MX359570B - Proteinas de union que inhiben la interaccion en el receptor de vegf-a. - Google Patents
Proteinas de union que inhiben la interaccion en el receptor de vegf-a.Info
- Publication number
- MX359570B MX359570B MX2015010520A MX2015010520A MX359570B MX 359570 B MX359570 B MX 359570B MX 2015010520 A MX2015010520 A MX 2015010520A MX 2015010520 A MX2015010520 A MX 2015010520A MX 359570 B MX359570 B MX 359570B
- Authority
- MX
- Mexico
- Prior art keywords
- binding proteins
- vegf
- binding
- receptor interaction
- proteins
- Prior art date
Links
- 108091008324 binding proteins Proteins 0.000 title abstract 5
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 title abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 230000010799 Receptor Interactions Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000023732 binding proteins Human genes 0.000 abstract 4
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 abstract 1
- 102000008102 Ankyrins Human genes 0.000 abstract 1
- 108010049777 Ankyrins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 abstract 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08168166 | 2008-11-03 | ||
| PCT/EP2009/064483 WO2010060748A1 (en) | 2008-11-03 | 2009-11-03 | Binding proteins inhibiting the vegf-a receptor interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX359570B true MX359570B (es) | 2018-10-01 |
Family
ID=40149742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010520A MX359570B (es) | 2008-11-03 | 2009-11-03 | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
| MX2011004649A MX2011004649A (es) | 2008-11-03 | 2009-11-03 | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011004649A MX2011004649A (es) | 2008-11-03 | 2009-11-03 | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8901076B2 (enExample) |
| EP (2) | EP3785735A1 (enExample) |
| JP (2) | JP5954990B2 (enExample) |
| KR (1) | KR101698362B1 (enExample) |
| CN (2) | CN107011425B (enExample) |
| AU (1) | AU2009319204B2 (enExample) |
| BR (1) | BRPI0921469B1 (enExample) |
| CA (1) | CA2742241C (enExample) |
| DK (1) | DK2358746T3 (enExample) |
| ES (1) | ES2836948T3 (enExample) |
| IL (1) | IL212589A (enExample) |
| MX (2) | MX359570B (enExample) |
| NZ (1) | NZ592591A (enExample) |
| RU (2) | RU2650765C1 (enExample) |
| WO (1) | WO2010060748A1 (enExample) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4976412B2 (ja) | 2005-12-01 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
| KR101482483B1 (ko) | 2006-04-07 | 2015-01-15 | 에르피오 세러퓨틱스 인코포레이티드 | 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도 |
| AU2014243418B2 (en) * | 2010-04-30 | 2016-09-22 | Molecular Partners Ag | Modified binding proteins inhibiting the VEGF-A receptor interaction |
| AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| CN113278077A (zh) * | 2010-11-26 | 2021-08-20 | 分子组合公司 | 设计的与血清白蛋白结合的重复蛋白 |
| WO2012149439A2 (en) | 2011-04-29 | 2012-11-01 | Janssen Biotech, Inc. | Il4/il13 binding repeat proteins and uses |
| WO2012172054A1 (en) | 2011-06-16 | 2012-12-20 | Scil Proteins Gmbh | Modified multimeric ubiquitin proteins binding vegf-a |
| CA2850830A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| PT3553084T (pt) | 2011-11-16 | 2023-02-17 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou esqueleto não-ig anti-adm para prevenção ou redução de disfunção de órgãos ou insuficiência de órgãos num paciente possuindo uma doença crónica ou aguda ou condição aguda |
| SG11201402358RA (en) | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| IL283215B2 (en) | 2011-11-16 | 2024-05-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same |
| EP2780717B1 (en) | 2011-11-16 | 2016-12-21 | sphingotec GmbH | Adrenomedullin assays and methods for determining mature adrenomedullin |
| SG11201402354YA (en) | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
| ES2494190T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo |
| CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
| PL2846836T3 (pl) * | 2012-05-07 | 2020-01-31 | Allergan, Inc. | Sposób leczenia amd u pacjentów opornych na terapię anty- vegf |
| PT3858405T (pt) | 2012-06-01 | 2023-06-26 | Novartis Ag | Seringa |
| EP2867360B1 (en) | 2012-06-28 | 2019-05-08 | Molecular Partners AG | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| DE202012011016U1 (de) | 2012-07-03 | 2012-11-28 | Novartis Ag | Aflibercept-Spritze |
| AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
| DE202013000688U1 (de) | 2012-07-03 | 2013-03-05 | Novartis Ag | Glas-Spritze |
| EP2890389A1 (en) * | 2012-08-28 | 2015-07-08 | Novartis AG | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| DK3361260T3 (da) | 2012-10-02 | 2020-08-03 | Sphingotec Gmbh | En fremgangsmåde til at diagnosticere eller overvåge nyrefunktion |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| CN104937421B (zh) | 2013-01-08 | 2018-01-19 | 斯弗因高泰克有限公司 | 生长激素的禁食水平作为心血管风险的预测标志物 |
| JP6499087B2 (ja) * | 2013-02-26 | 2019-04-10 | ロシュ グリクアート アーゲー | 二重特異性ｔ細胞活性化抗原結合分子 |
| JP6649246B2 (ja) * | 2013-03-14 | 2020-02-19 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法 |
| CN108362885B (zh) | 2013-03-20 | 2021-05-14 | 斯弗因高泰克有限公司 | 用于指导血压下降疗法的肾上腺髓质素 |
| FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
| CN105209483B (zh) | 2013-05-31 | 2021-07-27 | 分子组合公司 | 与肝细胞生长因子结合的设计锚蛋白重复蛋白 |
| US20160137717A1 (en) | 2013-06-20 | 2016-05-19 | Gabriela Burian | Use of a vegf antagonist in treating choroidal neovascularisation |
| EP3010526A1 (en) | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating macular edema |
| WO2014203181A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Treatment of polypoidal choroidal vasculopathy |
| WO2015004616A1 (en) * | 2013-07-11 | 2015-01-15 | Novartis Ag | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
| BR112016000282A2 (pt) * | 2013-07-11 | 2017-12-12 | Novartis Ag | uso de antagonista de vegf em tratamento de retinopatia da prematuridade |
| KR102948178B1 (ko) | 2013-07-12 | 2026-04-10 | 아스텔라스 유에스 엘엘씨 | 안과적 질환을 치료하거나 예방하기 위한 방법 |
| EP3628324A1 (en) * | 2013-11-05 | 2020-04-01 | Allergan, Inc. | Method of treating conditions of the eye with an anti-vegf darpin |
| RU2702748C2 (ru) | 2014-05-12 | 2019-10-11 | Формикон Аг | Предварительно заполненный пластиковый шприц, содержащий антагонист vegf |
| US20160097781A1 (en) | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
| BR112017020986A2 (pt) * | 2015-04-02 | 2018-08-14 | Molecular Partners Ag. | proteínas de ligação recombinantes e seu uso |
| JP6841765B2 (ja) | 2015-04-24 | 2021-03-10 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 慢性腎疾患の発症のリスクを予測するための方法 |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| WO2017085253A1 (en) | 2015-11-18 | 2017-05-26 | Formycon Ag | Pre-filled plastic syringe containing a vegf antagonist |
| AU2016356717B2 (en) | 2015-11-18 | 2022-09-29 | Sio2 Medical Products, Inc. | Pharmaceutical package for ophthalmic formulations |
| RU2734958C2 (ru) | 2015-11-18 | 2020-10-26 | Формикон Аг | Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf |
| WO2018218013A2 (en) | 2017-05-24 | 2018-11-29 | Sio2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
| WO2017129685A1 (en) | 2016-01-26 | 2017-08-03 | Formycon Ag | Liquid formulation of a vegf antagonist |
| WO2017148904A1 (en) | 2016-02-29 | 2017-09-08 | Franz Grus | Predictive markers useful in the treatment of wet age-related macular degeneration |
| MY200300A (en) | 2016-04-21 | 2023-12-19 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining dpp3 and therapeutic methods |
| MA45493A (fr) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
| CN109716136B (zh) | 2016-07-08 | 2023-09-22 | 斯弗因高泰克有限公司 | 肾上腺髓质素用于评估急性心力衰竭患者的充血 |
| US10253094B2 (en) | 2016-07-20 | 2019-04-09 | Aerpio Therapeutics, Inc. | Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions |
| ES2953516T3 (es) | 2016-09-22 | 2023-11-14 | Molecular Partners Ag | Proteínas de unión recombinantes y su uso |
| EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| JP7727371B2 (ja) | 2016-12-16 | 2025-08-21 | アドレノメト アクチェンゲゼルシャフト | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
| WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
| EP3630043A1 (en) | 2017-05-24 | 2020-04-08 | Formycon AG | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
| US20200182885A1 (en) | 2017-05-30 | 2020-06-11 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfuntion |
| TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| CN111225976A (zh) * | 2017-08-18 | 2020-06-02 | 剑桥企业有限公司 | 模块化结合蛋白 |
| CA3076691A1 (en) | 2017-09-25 | 2019-03-28 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
| MX2020004072A (es) | 2017-10-18 | 2020-07-28 | Adrenomed Ag | Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm). |
| AU2018356370A1 (en) | 2017-10-24 | 2020-04-09 | Sphingotec Gmbh | Selenoprotein P for prediction of a first cardiovascular event |
| EP3700937A2 (en) | 2017-10-25 | 2020-09-02 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
| JP2021513077A (ja) | 2018-02-08 | 2021-05-20 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| US10894824B2 (en) | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
| JP2022514896A (ja) | 2018-12-20 | 2022-02-16 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心不全におけるセレノプロテインｐ |
| US20220211798A1 (en) | 2018-12-21 | 2022-07-07 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof |
| EP3980443A1 (en) | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Multispecific proteins |
| JP7612666B2 (ja) | 2019-08-15 | 2025-01-14 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 小児患者における腎機能を診断若しくはモニタリングする、又は腎機能障害を診断する方法 |
| JP2022546061A (ja) | 2019-08-30 | 2022-11-02 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ショック症治療のための治療法の誘導および／または治療法の監視 |
| BR112022011177A2 (pt) | 2019-12-11 | 2022-09-27 | Molecular Partners Ag | Domínios de repetição de anquirina projetados com resíduos de superfície alterados |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| US20230104578A1 (en) | 2020-02-27 | 2023-04-06 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| US20230250166A1 (en) | 2020-02-27 | 2023-08-10 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
| BR112022015215A2 (pt) | 2020-02-27 | 2022-10-11 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 para orientação, monitoramento e estratificação de terapia de anticorpos nt-adm em pacientes com choque |
| JP2023518380A (ja) | 2020-03-16 | 2023-05-01 | アドレノメト アクチェンゲゼルシャフト | コロナウイルスに感染した患者におけるプロアドレノメデュリンまたはそのフラグメント、およびアドレノメデュリンに対する結合剤による治療 |
| CN115769076A (zh) | 2020-03-16 | 2023-03-07 | 4Teen4制药有限公司 | 感染冠状病毒的患者中的dpp3 |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| WO2021224686A1 (en) | 2020-05-06 | 2021-11-11 | Molecular Partners Ag | Novel ankyrin repeat binding proteins and their uses |
| EP4149959A1 (en) | 2020-05-14 | 2023-03-22 | Molecular Partners AG | Multispecific proteins |
| EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
| CA3202358A1 (en) | 2020-12-16 | 2022-06-23 | Andreas BOSSHART | Novel slow-release prodrugs |
| IL305677A (en) | 2021-03-09 | 2023-11-01 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| JP2024508969A (ja) | 2021-03-09 | 2024-02-28 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ |
| JP2024509890A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | プロテアーゼ切断可能なプロドラッグ |
| US20240150475A1 (en) | 2021-03-09 | 2024-05-09 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| WO2022231930A1 (en) | 2021-04-26 | 2022-11-03 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| US20240272178A1 (en) | 2021-06-18 | 2024-08-15 | Sphingotec Gmbh | A method for predicting sepsis and septic shock |
| WO2023275099A1 (en) | 2021-06-29 | 2023-01-05 | Berysol Gmbh | Composite biomarker for the identification of selenium deficiency in a bodily fluid |
| EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
| EP4447990A1 (en) | 2021-12-14 | 2024-10-23 | Molecular Partners AG | Designed repeat domains with dual binding specificity and their use |
| CA3254142A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | STABLE AQUEOUS FORMULATION OF AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM ANTIBODY FRAGMENT |
| IL318667A (en) | 2022-07-29 | 2025-03-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| AU2023315168A1 (en) | 2022-07-29 | 2025-02-13 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| WO2024028278A1 (en) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| WO2024059686A2 (en) * | 2022-09-15 | 2024-03-21 | The Regents Of The University Of California | Darpin backbones and rigidified electron microscopy imaging scaffolds |
| EP4633659A1 (en) | 2022-12-15 | 2025-10-22 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for improvement of pulmonary function in critically ill patients |
| EP4673159A1 (en) | 2023-02-27 | 2026-01-07 | Molecular Partners AG | Darpins for use in reducing renal accumulation of drugs |
| CN120731367A (zh) | 2023-03-17 | 2025-09-30 | Pam治疗诊断有限公司 | 肽基甘氨酸α-酰胺化单加氧酶（PAM）的测定方法及其诊断用途 |
| JP2026513177A (ja) | 2023-03-29 | 2026-04-23 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血圧低下を有する重症患者における心筋保護及び心筋傷害の予防のためのｄｐｐ３阻害剤 |
| WO2025068313A1 (en) | 2023-09-25 | 2025-04-03 | Sphingotec Gmbh | A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025229075A1 (en) | 2024-05-03 | 2025-11-06 | Sphingotec Gmbh | A method for the specific determination of proenkephalin fragment 119-159 |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
| EP4675277A1 (en) | 2024-07-05 | 2026-01-07 | Predemtec AG | A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease |
| WO2026046968A1 (en) | 2024-08-26 | 2026-03-05 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binders for the treatment of endothelial dysfunction |
| WO2026046978A1 (en) | 2024-08-26 | 2026-03-05 | Pam Theragnostics Gmbh | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| DE69832970T2 (de) | 1997-04-07 | 2006-08-10 | Genentech, Inc., South San Francisco | Humanisierte antikörper und verfahren zu ihrer herstellung |
| IL132240A0 (en) | 1997-04-07 | 2001-03-19 | Genentech Inc | Anti-vegf antibodies |
| JP4086325B2 (ja) | 1997-04-23 | 2008-05-14 | プリュックテュン，アンドレアス | 標的分子と相互作用する（ポリ）ペプチドをコードする核酸分子の同定方法 |
| PT1137812E (pt) | 1998-12-02 | 2007-05-31 | Adnexus Therapeutics Inc | Fusões adn-proteína e suas utilizações |
| MXPA01012630A (es) | 1999-06-08 | 2002-07-22 | Regeneron Pharma | Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas. |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| JP5291279B2 (ja) * | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| RU2299208C2 (ru) * | 2001-05-08 | 2007-05-20 | Шеринг Акциенгезельшафт | Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3 |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005056764A2 (en) * | 2003-12-05 | 2005-06-23 | Compound Therapeutics, Inc. | Inhibitors of type 2 vascular endothelial growth factor receptors |
| EP2292246A1 (en) * | 2004-11-12 | 2011-03-09 | Bayer Schering Pharma Aktiengesellschaft | Recombinant Newcastle Disease Virus |
| HUE034109T2 (en) * | 2005-03-25 | 2018-01-29 | Regeneron Pharma | VEGF antagonist formulations |
| MX2008000345A (es) | 2005-07-08 | 2008-04-02 | Univ Zuerich | Visualizacion en fagos usando transcolocacion contraduccional de polipeptidos de fusion. |
| JP5537946B2 (ja) * | 2006-11-22 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬 |
| EP2125016A2 (en) * | 2007-02-01 | 2009-12-02 | Genetech, Inc. | Combination therapy with angiogenesis inhibitors |
| US20100144599A1 (en) | 2007-02-02 | 2010-06-10 | Bristol-Myers Squibb Company | Vegf pathway blockade |
-
2009
- 2009-11-03 MX MX2015010520A patent/MX359570B/es unknown
- 2009-11-03 KR KR1020117009012A patent/KR101698362B1/ko active Active
- 2009-11-03 CN CN201710092752.9A patent/CN107011425B/zh active Active
- 2009-11-03 WO PCT/EP2009/064483 patent/WO2010060748A1/en not_active Ceased
- 2009-11-03 EP EP20196328.7A patent/EP3785735A1/en not_active Withdrawn
- 2009-11-03 MX MX2011004649A patent/MX2011004649A/es unknown
- 2009-11-03 ES ES09756279T patent/ES2836948T3/es active Active
- 2009-11-03 US US13/126,821 patent/US8901076B2/en active Active
- 2009-11-03 CA CA2742241A patent/CA2742241C/en active Active
- 2009-11-03 RU RU2015108838A patent/RU2650765C1/ru active
- 2009-11-03 DK DK09756279.7T patent/DK2358746T3/da active
- 2009-11-03 RU RU2011122201/10A patent/RU2550258C2/ru active
- 2009-11-03 AU AU2009319204A patent/AU2009319204B2/en active Active
- 2009-11-03 JP JP2011533752A patent/JP5954990B2/ja active Active
- 2009-11-03 BR BRPI0921469-0A patent/BRPI0921469B1/pt active IP Right Grant
- 2009-11-03 NZ NZ592591A patent/NZ592591A/en unknown
- 2009-11-03 EP EP09756279.7A patent/EP2358746B1/en active Active
- 2009-11-03 CN CN2009801536047A patent/CN102272148A/zh active Pending
-
2011
- 2011-04-28 IL IL212589A patent/IL212589A/en active IP Right Grant
-
2014
- 2014-10-28 US US14/525,553 patent/US20150344539A1/en not_active Abandoned
-
2015
- 2015-03-17 JP JP2015053249A patent/JP6329503B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ592591A (en) | 2012-04-27 |
| EP2358746A1 (en) | 2011-08-24 |
| JP6329503B2 (ja) | 2018-05-23 |
| EP2358746B1 (en) | 2020-09-16 |
| EP3785735A1 (en) | 2021-03-03 |
| JP2012507271A (ja) | 2012-03-29 |
| DK2358746T3 (da) | 2020-12-21 |
| WO2010060748A1 (en) | 2010-06-03 |
| RU2550258C2 (ru) | 2015-05-10 |
| KR101698362B1 (ko) | 2017-01-20 |
| IL212589A0 (en) | 2011-07-31 |
| CN102272148A (zh) | 2011-12-07 |
| CN107011425A (zh) | 2017-08-04 |
| MX2011004649A (es) | 2011-05-30 |
| US8901076B2 (en) | 2014-12-02 |
| CA2742241C (en) | 2019-12-10 |
| IL212589A (en) | 2017-01-31 |
| AU2009319204A1 (en) | 2010-06-03 |
| BRPI0921469A2 (pt) | 2016-01-12 |
| JP2015133978A (ja) | 2015-07-27 |
| JP5954990B2 (ja) | 2016-07-20 |
| US20150344539A1 (en) | 2015-12-03 |
| CA2742241A1 (en) | 2010-06-03 |
| RU2011122201A (ru) | 2012-12-10 |
| CN107011425B (zh) | 2021-01-01 |
| RU2650765C1 (ru) | 2018-04-17 |
| ES2836948T3 (es) | 2021-06-28 |
| BRPI0921469B1 (pt) | 2022-01-18 |
| US20110207668A1 (en) | 2011-08-25 |
| KR20110082528A (ko) | 2011-07-19 |
| AU2009319204B2 (en) | 2014-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012502115A1 (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| TW201129377A (en) | Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho | |
| SG178602A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| PH12012500774A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| PH12012500815A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| MX2012004415A (es) | Inmunoglobulinas de dominio variable doble y usos de las mismas. | |
| MX2012001262A (es) | Inmunoglobulinas de dominio variable doble y usos de las misma. | |
| MX2011011669A (es) | Inmunoglobulinas de dominio variable dual y usos de las misma. | |
| PH12012502523A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| WO2012088290A3 (en) | Tri-variable domain binding proteins and uses thereof | |
| NZ754051A (en) | Novel antibodies and uses thereof | |
| MY159396A (en) | Compositions and methods for antibodies targeting complement protein c5 | |
| EP4338754A3 (en) | Antigen binding proteins | |
| MY165273A (en) | Anti-cd48 antibodies and uses thereof | |
| CY1119567T1 (el) | Θεραπευτικα πεπτιδια | |
| PH12014500167A1 (en) | Tnf-alpha antigen-binding proteins with increased fcrn binding | |
| PH12013500207A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| PH12013500337A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| PH12013500867A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| MX366223B (es) | Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. | |
| EA201500371A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ | |
| MX338421B (es) | Anticuerpos fosfoespecificos que reconocen la proteina tau. | |
| WO2009138494A3 (en) | Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors | |
| WO2010129048A3 (en) | Therapeutic compounds |